PortalPublikationenConcordance of HER2 status in primary tumour and lymph node ...

Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma

Standard

Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. / König, Alexandra M; Reeh, Matthias; Dancau, Ana Maria; Rathjens, Merrit; Gros, Stephanie; Uzunoglu, Faik G; Bockhorn, Maximilian; Simon, Ronald; Sauter, Guido; Marx, Andreas; Izbicki, Jakob R.

in: ANTICANCER RES, Jahrgang 33, Nr. 11, 01.11.2013, S. 4975-82.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

König, AM, Reeh, M, Dancau, AM, Rathjens, M, Gros, S, Uzunoglu, FG, Bockhorn, M, Simon, R, Sauter, G, Marx, A & Izbicki, JR 2013, 'Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma', ANTICANCER RES, Jg. 33, Nr. 11, S. 4975-82.

APA

König, A. M., Reeh, M., Dancau, A. M., Rathjens, M., Gros, S., Uzunoglu, F. G., Bockhorn, M., Simon, R., Sauter, G., Marx, A., & Izbicki, J. R. (2013). Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. ANTICANCER RES, 33(11), 4975-82.

Vancouver

König AM, Reeh M, Dancau AM, Rathjens M, Gros S, Uzunoglu FG et al. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. ANTICANCER RES. 2013 Nov 1;33(11):4975-82.

Bibtex

@article{5538088a703d42ffb045a903e2390c2d,
title = "Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma",
abstract = "BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an important prognostic factor in several types of solid tumours. Although HER2 seems not to influence survival in esophageal carcinomas, an impact of the HER2 status of disseminated tumour cells (DTCs) on survival has been shown. The aim of our study was to investigate the significance of the HER2 status in primary esophageal carcinomas and matched lymph node metastases.MATERIALS AND METHODS: The HER2 status of primary tumours and matched lymph node metastases were analysed for 158 patients with esophageal carcinoma using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).RESULTS: The study specimen included 90 adenocarcinomas (AC) and 68 squamous cell carcinomas (SCC). HER2 amplification was found in 12% and overexpression in 8.9% of all primary tumours. HER2 amplification was identical in the primary tumour and lymph node metastases in all AC and in 75% of SCC. Discordant-positive HER2 lymph node status and negative primary tumour status was found in 4.4% of AC and 1.5% of SCC in FISH analyses. No significant associations were found between HER2 amplification/overexpression and overall survival.CONCLUSION: HER2 gene status remains highly conserved in metastatic esophageal carcinoma. Discrepancies occur rarely between primary tumour and lymph node metastases and might be due to heterogeneity of the HER2 status of the primary tumour. This could be the reason for heterogeneity of DTCs and may result in metastasis of only a subset of tumour cells.",
keywords = "Adenocarcinoma, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Esophageal Neoplasms, Female, Follow-Up Studies, Gene Amplification, Humans, Immunoenzyme Techniques, In Situ Hybridization, Fluorescence, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Receptor, erbB-2, Survival Rate, Tissue Array Analysis, Tumor Markers, Biological",
author = "K{\"o}nig, {Alexandra M} and Matthias Reeh and Dancau, {Ana Maria} and Merrit Rathjens and Stephanie Gros and Uzunoglu, {Faik G} and Maximilian Bockhorn and Ronald Simon and Guido Sauter and Andreas Marx and Izbicki, {Jakob R}",
year = "2013",
month = nov,
day = "1",
language = "English",
volume = "33",
pages = "4975--82",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

RIS

TY - JOUR

T1 - Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma

AU - König, Alexandra M

AU - Reeh, Matthias

AU - Dancau, Ana Maria

AU - Rathjens, Merrit

AU - Gros, Stephanie

AU - Uzunoglu, Faik G

AU - Bockhorn, Maximilian

AU - Simon, Ronald

AU - Sauter, Guido

AU - Marx, Andreas

AU - Izbicki, Jakob R

PY - 2013/11/1

Y1 - 2013/11/1

N2 - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an important prognostic factor in several types of solid tumours. Although HER2 seems not to influence survival in esophageal carcinomas, an impact of the HER2 status of disseminated tumour cells (DTCs) on survival has been shown. The aim of our study was to investigate the significance of the HER2 status in primary esophageal carcinomas and matched lymph node metastases.MATERIALS AND METHODS: The HER2 status of primary tumours and matched lymph node metastases were analysed for 158 patients with esophageal carcinoma using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).RESULTS: The study specimen included 90 adenocarcinomas (AC) and 68 squamous cell carcinomas (SCC). HER2 amplification was found in 12% and overexpression in 8.9% of all primary tumours. HER2 amplification was identical in the primary tumour and lymph node metastases in all AC and in 75% of SCC. Discordant-positive HER2 lymph node status and negative primary tumour status was found in 4.4% of AC and 1.5% of SCC in FISH analyses. No significant associations were found between HER2 amplification/overexpression and overall survival.CONCLUSION: HER2 gene status remains highly conserved in metastatic esophageal carcinoma. Discrepancies occur rarely between primary tumour and lymph node metastases and might be due to heterogeneity of the HER2 status of the primary tumour. This could be the reason for heterogeneity of DTCs and may result in metastasis of only a subset of tumour cells.

AB - BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an important prognostic factor in several types of solid tumours. Although HER2 seems not to influence survival in esophageal carcinomas, an impact of the HER2 status of disseminated tumour cells (DTCs) on survival has been shown. The aim of our study was to investigate the significance of the HER2 status in primary esophageal carcinomas and matched lymph node metastases.MATERIALS AND METHODS: The HER2 status of primary tumours and matched lymph node metastases were analysed for 158 patients with esophageal carcinoma using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH).RESULTS: The study specimen included 90 adenocarcinomas (AC) and 68 squamous cell carcinomas (SCC). HER2 amplification was found in 12% and overexpression in 8.9% of all primary tumours. HER2 amplification was identical in the primary tumour and lymph node metastases in all AC and in 75% of SCC. Discordant-positive HER2 lymph node status and negative primary tumour status was found in 4.4% of AC and 1.5% of SCC in FISH analyses. No significant associations were found between HER2 amplification/overexpression and overall survival.CONCLUSION: HER2 gene status remains highly conserved in metastatic esophageal carcinoma. Discrepancies occur rarely between primary tumour and lymph node metastases and might be due to heterogeneity of the HER2 status of the primary tumour. This could be the reason for heterogeneity of DTCs and may result in metastasis of only a subset of tumour cells.

KW - Adenocarcinoma

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Squamous Cell

KW - Esophageal Neoplasms

KW - Female

KW - Follow-Up Studies

KW - Gene Amplification

KW - Humans

KW - Immunoenzyme Techniques

KW - In Situ Hybridization, Fluorescence

KW - Lymphatic Metastasis

KW - Male

KW - Middle Aged

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Prognosis

KW - Receptor, erbB-2

KW - Survival Rate

KW - Tissue Array Analysis

KW - Tumor Markers, Biological

M3 - SCORING: Journal article

C2 - 24222138

VL - 33

SP - 4975

EP - 4982

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 11

ER -